Stockscreener 앱 받기
25.17
8.04%
-2.20
시간 외 거래:
25.15
-0.02
-0.08%
전일 마감가:
$27.37
열려 있는:
$27.17
하루 거래량:
7.56M
Relative Volume:
1.27
시가총액:
$3.20B
수익:
순이익/손실:
$-472.34M
주가수익비율:
-6.0711
EPS:
-4.1459
순현금흐름:
$-340.33M
1주 성능:
-11.72%
1개월 성능:
-14.74%
6개월 성능:
-29.12%
1년 성능:
-27.53%
1일 변동 폭
$24.94
$27.34
1주일 범위
$24.94
$28.84
52주 변동 폭
$24.94
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
25.17 | 3.20B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-15 | 개시 | UBS | Buy |
| 2026-05-28 | 개시 | Lake Street | Buy |
| 2026-05-27 | 재개 | Truist | Buy |
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
4 High-Risk Stocks Built for Big Returns - The Motley Fool
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Total equity of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - Yahoo Finance
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Viking Therapeutics Inc (Derivatives) to Chinese Yuan Price Today | Live VKTX to CNY Converter & Exchange Rate - CryptoRank
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
Viking Therapeutics Inc (Derivatives) - CryptoRank
Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months - Yahoo Finance
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
VKTX Advances Obesity Program With New Oral Maintenance Study - Zacks Investment Research
Viking Therapeutics starts oral trial as Truist targets Viking Therapeutics stock at USD 87 - AD HOC NEWS
Viking Therapeutics Starts VK2735 Obesity Maintenance Trial - grafa.com
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - Yahoo Finance
VKTX Down 16% in a Month: Time to Invest or Exit the Stock? - TradingView
Viking Therapeutics begins oral VK2735 maintenance trial in obesity - Mugglehead Investment Magazine
Viking Therapeutics initiates oral maintenance dosing study - Investing.com
Viking Therapeutics Inc (Derivatives) price today, VKTX to USD live price, marketcap and chart - CoinMarketCap
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - PR Newswire
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity - Yahoo Finance
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock - The Motley Fool
Here Are My Top 4 Stocks to Buy in October - The Motley Fool
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTXObesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis - Simply Wall Street
Viking Therapeutics Inc (MIL:1VKTX) Stock Price, Trades & News - GuruFocus
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) - Yahoo! Finance Canada
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? - Yahoo Finance
Prediction: This Stock Could Double Over the Next 5 Years - The Motley Fool
Inventory turnover of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Viking Therapeutics Slides as Financing Overhang Appears to Weigh on Shares - Quiver Quantitative
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - sg.finance.yahoo.com
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - Yahoo Finance
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - Yahoo Finance
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Therapeutics Raises Capital via Equity and Convertibles - TipRanks
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| MARIANNA MANCINI | Officer |
Jul 29 '26 |
Proposed Sale |
33.47 |
18,217 |
609,636 |
0 |
| GREG ZANTE | Officer |
Jul 29 '26 |
Proposed Sale |
33.47 |
21,217 |
710,141 |
0 |
| BRIAN LIAN | Officer |
Jul 29 '26 |
Proposed Sale |
33.32 |
148,517 |
4,947,888 |
0 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
| Aubuchon Neil William | Chief Commercial Officer |
Mar 10 '26 |
Buy |
33.50 |
4,475 |
149,912 |
4,475 |
| MARIANNA MANCINI | Officer |
Jan 05 '26 |
Proposed Sale |
32.98 |
57,661 |
1,901,406 |
0 |
| GREG ZANTE | Officer |
Jan 05 '26 |
Proposed Sale |
32.98 |
57,661 |
1,901,470 |
0 |
| BRIAN LIAN | Officer |
Jan 05 '26 |
Proposed Sale |
32.96 |
233,409 |
7,692,134 |
0 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
4.11%
자본화:
|
볼륨(24시간):